<DOC>
	<DOCNO>NCT00269217</DOCNO>
	<brief_summary>This 12-week clinical trial patient primary hypercholesterolemia mixed hyperlipidemia , study effect coadministered MK0524B lipid . There 6 schedule clinic visit , 7 treatment arm .</brief_summary>
	<brief_title>Lipid Efficacy Study ( 0524B-022 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipidemia , Familial Combined</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type V</mesh_term>
	<mesh_term>Lipidoses</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Patients 18 85 year age primary hypercholesterolemia mixed hyperlipidemia LDLC 130 190 mg/L ( Category I ) 130 160 mg/L ( Category II ) triglycerides &lt; /= 350 mg/dL . A condition , opinion investigator , might pose risk patient interfere participate study Patients &lt; 80 % compliance Patients certain medical condition Patients take certain concomitant medication and/or unstable dos medication Or history CHD/CHD equivalent diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>